pembrolizumab,enfortumab vedotin
merck,astellas,seagen
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'gusm', 'ev-103', ' vedo', 'enfortumab', 'urothelial', 'pembro']
 we spoke with who shared results from cohort k of ev-103 enfortumab vedotin plus pembrolizumab showed high overall response rates with rapid responses #esmo22 #urothelialcarcinoma #gusm
The Video Journal of Oncology is dedicated to providing trusted information to improve knowledge, understanding and awareness of cancer. Intended for HCPs only.